{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:35:04Z","timestamp":1793658904984,"version":"4.5.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ck0106447h0002, 21ck0106711h0001, 21ck0106710h0001, 22lk0201164h0001, and 22lk0201148h0002"],"award-info":[{"award-number":["19ck0106447h0002, 21ck0106711h0001, 21ck0106710h0001, 22lk0201164h0001, and 22lk0201148h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04428-0","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:04:00Z","timestamp":1780909440000},"page":"2473-2480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-2765","authenticated-orcid":false,"given":"Hideaki","family":"Bando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-6802","authenticated-orcid":false,"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-5044","authenticated-orcid":false,"given":"Yuji","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Manaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-174X","authenticated-orcid":false,"given":"Kun-Huei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Watsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8003-358X","authenticated-orcid":false,"given":"Vasily N.","family":"Aushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-3053","authenticated-orcid":false,"given":"Adham","family":"Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-5232","authenticated-orcid":false,"given":"Minetta C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1595-2453","authenticated-orcid":false,"given":"Ichiro","family":"Takemasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-555X","authenticated-orcid":false,"given":"Daisuke","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-6855","authenticated-orcid":false,"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-8832","authenticated-orcid":false,"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-6682","authenticated-orcid":false,"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"4428_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"4428_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.6004\/jnccn.2024.0047","volume":"22","author":"RM Ness","year":"2024","unstructured":"Ness, R. M. et al. NCCN Guidelines\u00ae Insights: Colorectal Cancer Screening, version 1.2024. J. Natl Compr. Canc. Netw. 22, 438\u2013446 (2024).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"4428_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argiles","year":"2020","unstructured":"Argiles, G. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291\u20131305 (2020).","journal-title":"Ann. Oncol."},{"key":"4428_CR4","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra, E. A. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery: a five-year follow-up of the RAPIDO trial. Ann. Surg. 278, e766\u2013e772 (2023).","journal-title":"Ann. Surg."},{"key":"4428_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy, T. et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann. Oncol. 35, 873\u2013881 (2024).","journal-title":"Ann. Oncol."},{"key":"4428_CR6","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO.24.01160","volume":"42","author":"AJ Scott","year":"2024","unstructured":"Scott, A. J. et al. Management of locally advanced rectal cancer: ASCO guideline. J. Clin. Oncol. 42, 3355\u20133375 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4428_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4428_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger, B. et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14, 1208\u20131215 (2013).","journal-title":"Lancet Oncol."},{"key":"4428_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."},{"key":"4428_CR10","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"4428_CR11","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4428_CR12","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat. Med. 31, 4291\u20134300 (2025).","journal-title":"Nat. Med."},{"key":"4428_CR13","first-page":"381","volume":"11","author":"T Emura","year":"2004","unstructured":"Emura, T., Nakagawa, F., Fujioka, A., Ohshimo, H. & Kitazato, K. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol. Rep. 11, 381\u2013387 (2004).","journal-title":"Oncol. Rep."},{"key":"4428_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4428_CR15","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25, 3456\u20133461 (2007).","journal-title":"J. Clin. Oncol."},{"key":"4428_CR16","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117\u20133125 (2009).","journal-title":"J. Clin. Oncol."},{"key":"4428_CR17","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi, H. et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 112, 2915\u20132920 (2021).","journal-title":"Cancer Sci."},{"key":"4428_CR18","doi-asserted-by":"publisher","first-page":"S1268","DOI":"10.1016\/j.annonc.2023.10.020","volume":"34","author":"S Lonardi","year":"2023","unstructured":"Lonardi, S. et al. LBA28 The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. Ann. Oncol. 34, S1268\u2013S1269 (2023).","journal-title":"Ann. Oncol."},{"key":"4428_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4428_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A de Gramont","year":"2012","unstructured":"de Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225\u20131233 (2012).","journal-title":"Lancet Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04428-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:01:41Z","timestamp":1784210501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04428-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4428"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04428-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.B. reports research funding from Ono Pharmaceutical and honoraria from Ono Pharmaceutical, Taiho Pharmaceutical and Guardant Health. J.W. reports honoraria for lectures from Johnson & Johnson, Covidien Japan, Eli Lilly, Terumo and Takeda Pharmaceutical, and research funding from Covidien Japan, Terumo and Stryker Japan, all outside the submitted work. Y.T., K.H., Y.M., M.T., D.M., A.K., M.F., I.T. and D.K. declare no competing interests. M.K. reports honoraria from Chugai Pharmaceutical, Eli Lilly Japan and Takeda Pharmaceutical. N.M. reports honoraria from multiple companies, including Abbott, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, Guardant Health, Johnson & Johnson, Kyowa Kirin, Merck, MSD, Novartis, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical and others, and research funding to the institution from Covidien Japan, Johnson & Johnson, Taiho Pharmaceutical, Terumo and others. E.O. reports research funding from Guardant Health and honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Bayer, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan and Bristol Myers Squibb. Y.K. reports research funding from Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Amgen, MSD, Daiichi Sankyo, Eisai, Sysmex and Takeda Pharmaceutical, and honoraria from Bayer, Chugai Pharmaceutical, Taiho Pharmaceutical, Merck, MSD, Ono Pharmaceutical, Daiichi Sankyo, Eisai, Guardant Health, Astellas and Takeda Pharmaceutical. M.S. reports honoraria from Eli Lilly, Takeda Pharmaceutical, Merck Serono, Ono Pharmaceutical and Taiho Pharmaceutical. M.T. reports research funding from Ono Pharmaceutical and Nippon Boehringer Ingelheim, and honoraria from Chugai Pharmaceutical, MSD, Taiho Pharmaceutical, Ono Pharmaceutical and Bristol Myers Squibb. K.Y. reports honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Eli Lilly, MSD and Bristol Myers Squibb. Y.-H.L. reports honoraria from Amgen, Bayer, Bristol Myers Squibb, Merck, Ono Pharmaceutical and Takeda Pharmaceutical. K.-H.Y. reports honoraria from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, MSD, Merck, Novartis, Ono Pharmaceutical, Pierre Fabre, Pfizer, Roche and Takeda Pharmaceutical. Y.W. and Y.Y. are employees of EPS Corporation. S.S., V.N.A., A.J., M.R., M.C.L. and A.A. are employees of Natera. A.S reports research funding to the institution from Taiho Pharmaceutical, Boehringer Ingelheim, Bayer, Chugai Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Pentax Medical Devices, MSD, Daiichi Sankyo\/UCB Japan, Merck Pharmaceutical FerroptoCure and Shionogi Pharmaceutical, all outside the submitted work. Y.N. reports advisory roles for Guardant Health; research funding from Exact Sciences, Pfizer and Shionogi; and speaker fees from MSD, Merck Biopharma, Daiichi Sankyo, Chugai Pharmaceutical and Guardant Health Japan. Q.S. reports consulting or advisory roles for Bayer, Boehringer Ingelheim, Regeneron, Genmab, AbbVie, Exelixis and others, and research funding to the institution from Regeneron, Bristol Myers Squibb, Roche\/Genentech, Janssen and Novartis. H.T. reports honoraria from Ono Pharmaceutical, Merck Biopharma, Eli Lilly Japan, Chugai Pharmaceutical and Takeda Pharmaceutical, and research funding from Takeda Pharmaceutical, Daiichi Sankyo and Ono Pharmaceutical. T.Y. reports research funding from Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, MSD, Bristol Myers Squibb, Caris MPI, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., Miyarisan Pharmaceutical, Natera, Nippon Boehringer Ingelheim, Pfizer, Sysmex and Takeda Pharmaceutical; honoraria from Chugai Pharmaceutical, Merck Biopharma, Ono Pharmaceutical and Takeda Pharmaceutical; and consulting fees from Sumitomo and Indivumed. T.K. reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Ono Pharmaceutical and Eli Lilly.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}